FUNDAMENTALS · Fundamentals · US Healthcare

Apogee Therapeutics (APGE) Fundamentals 2026 — Revenue Analysis | SniperIQ

Apogee Therapeutics (APGE) is a US-listed Healthcare company in Biotechnology with a market capitalization of $8.3B, trading at

34.19 on the NASDAQ. This SniperIQ fundamentals page covers Apogee Therapeutics's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$8.3B
Net Margin0.0%

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Apogee Therapeutics's market cap?

Apogee Therapeutics (APGE) has a market capitalization of approximately $8.3B, trading at

34.19 on the NASDAQ. Market cap moves with the live share price.

What is Apogee Therapeutics's P/E ratio?

Apogee Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 7.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Apogee Therapeutics?

Apogee Therapeutics runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

Does Apogee Therapeutics pay a dividend?

Apogee Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Apogee Therapeutics financially healthy?

Apogee Therapeutics carries a debt-to-equity ratio of 0.01x and a current ratio of 32.59x, with a market beta of 0.33. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Apogee Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Apogee Therapeutics (APGE) the key facts are: market cap $8.3B, 52-week range 34.34-134.4. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Apogee Therapeutics's full fundamentals live

Get Apogee Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Qiagen (QGEN) fundamentals · Xiamen Kingdomway Group (002626) fundamentals · Vcanbio Cell & Gene Engineering (600645) fundamentals · Bio-Rad Laboratories (BIO) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons